CTAS vs PFE · P/E 51, rev $11.26B vs P/E 20, rev $15.03B
Cintas Corporation (CTAS) versus Pfizer Inc (PFE) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Latest reported PFE revenue for 2026-06-28 was $15.03B. Net income was -$248.0M. Revenue was up 4.0% from 2026-03-29 to 2026-06-28. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
Not investment advice. Open the CTAS and PFE stock pages for the full models.
Not investment advice.